What is Biotheus?
Founded in 2018 and headquartered in China, Biotheus is a specialized biotechnology enterprise dedicated to the discovery and development of innovative therapies for malignant tumors and autoimmune diseases. The company operates at the intersection of advanced molecular biology and clinical medicine, focusing on high-impact therapeutic areas that require sophisticated, targeted interventions. By maintaining a rigorous focus on scientific excellence, Biotheus has established itself as a key contributor to the evolving landscape of global life sciences, aiming to transform patient outcomes through precision medicine.
How much funding has Biotheus raised?
Biotheus has raised a total of $100M across 1 funding round:
Other Financing Round
$100M
Other Financing Round (2021): $100M with participation from Cowin Capital, IDG Capital Partners, Shiyu Capital, Kunlun Capital, General Atlantic, Huajin Investment, CPE, Highlight Capital, and New Alliance Capital
Key Investors in Biotheus
Cowin Capital
A prominent domestic venture capital firm established in 2000, known for its high success rate in guiding portfolio companies through the IPO process in China's capital markets.
IDG Capital Partners
A Beijing-based investment firm founded in 1992 that specializes in private equity, venture capital, and strategic mergers and acquisitions across diverse sectors.
General Atlantic
A global growth equity firm providing capital and strategic support to high-growth companies, with a specific focus on healthcare, life sciences, and technology sectors.
What's next for Biotheus?
With the successful closure of this major strategic investment, Biotheus is poised to enter a critical phase of expansion. The company is expected to prioritize the advancement of its lead candidates through clinical trials while simultaneously strengthening its internal research infrastructure. Strategic focus will likely remain on enhancing its proprietary technology platforms to maintain a competitive edge in the oncology and immunology markets. Furthermore, the infusion of capital provides the necessary runway to explore potential international partnerships and regulatory milestones, ensuring that the firm remains at the forefront of medical innovation as it scales its enterprise-level operations.
See full Biotheus company page
